To Meet Or Not To Meet? That Is CDER’s Question As Cmte. Cancellations Rise

Clinical development and regulatory review are already full of uncertainties, but this year FDA introduced a new twist - canceling and postponing advisory committee meetings. Almost half of the scheduled meetings have not taken place, which may or may not be a bad sign for industry